VYNE

VYNE Therapeutics Inc.

2.21 USD
+0.08 (+3.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

VYNE Therapeutics Inc. stock is up 27.01% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 July’s closed higher than June.

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.